Published in Life Sci on March 18, 2009
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Evaluation of F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Res (2011) 1.00
Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse (2011) 0.98
Nicotinic acetylcholine receptors in rat forebrain that bind ¹⁸F-nifene: relating PET imaging, autoradiography, and behavior. Synapse (2012) 0.90
PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate. J Nucl Med (2012) 0.90
Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography. Biochem Pharmacol (2015) 0.85
5-(5-(6-[(11)C]methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)-1H-indole as a potential PET radioligand for imaging cerebral α7-nAChR in mice. Bioorg Med Chem (2012) 0.85
Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-¹⁸F-fluoropropyl)pyridine (¹⁸F-Nifrolene) using PET. Nucl Med Biol (2012) 0.83
Synthesis and evaluation of new radioligands [(11)C]A-833834 and [(11)C]A-752274 for positron-emission tomography of α7-nicotinic acetylcholine receptors. Nucl Med Biol (2013) 0.83
Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse (2011) 0.82
A philosophy for CNS radiotracer design. Acc Chem Res (2014) 0.79
Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine). Nucl Med Biol (2011) 0.79
Spiroindolines identify the vesicular acetylcholine transporter as a novel target for insecticide action. PLoS One (2012) 0.79
Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology (Berl) (2015) 0.79
Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of alpha4beta2 nicotinic acetylcholine receptors (alpha4beta2-nAChRs) in the brain with positron emission tomography. Bioorg Med Chem (2009) 0.78
Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. Nucl Med Biol (2014) 0.76
Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging (2016) 0.76
PET Imaging of the Human Nicotinic Cholinergic Pathway in Atherosclerosis. Curr Cardiol Rep (2015) 0.76
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors. Curr Top Med Chem (2016) 0.75
Improved Syntheses of Precursors for PET Radioligands [F]XTRA and [F]AZAN. Tetrahedron Lett (2010) 0.75
International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev (1999) 2.76
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry (2006) 2.53
Neuronal nicotinic receptors in the human brain. Prog Neurobiol (2000) 2.31
Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab (1993) 2.28
PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun (2008) 2.16
Human neuronal nicotinic receptors. Prog Neurobiol (1997) 1.67
Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med (2008) 1.51
Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem (1997) 1.41
Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des (2006) 1.41
Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol (2006) 1.22
Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synapse (2003) 1.21
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med (2000) 1.20
6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse (2004) 1.11
Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med (2003) 1.11
Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain (2006) 1.11
Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition. Synapse (2007) 1.09
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2'-fluoro-3'-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist. J Med Chem (2004) 1.09
A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. Neuropharmacology (1996) 1.05
Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. Neuroimage (2007) 1.04
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. Nucl Med Biol (2005) 1.03
Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology (2004) 1.02
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-substituted deschloroepibatidine analogues. Novel nicotinic antagonists. J Med Chem (2005) 1.01
The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des (2006) 1.00
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res (2000) 0.98
2-[18F]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl Med Biol (1998) 0.98
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. J Nucl Med (1999) 0.93
Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry (2001) 0.92
6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci (2000) 0.91
Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem (2008) 0.88
Norchloro-fluoro-homoepibatidine (NCFHEB) - a promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. Eur Neuropsychopharmacol (2007) 0.88
In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro-fluoro-homoepibatidine. Synapse (2008) 0.87
Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl (2000) 0.87
Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nucl Med Biol (1997) 0.86
Derivatives of (-)-7-methyl-2-(5-(pyridinyl)pyridin-3-yl)-7-azabicyclo[2.2.1]heptane are potential ligands for positron emission tomography imaging of extrathalamic nicotinic acetylcholine receptors. J Med Chem (2007) 0.86
Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. J Pharmacol Exp Ther (2004) 0.85
PET quantification of specific binding of carbon-11-nicotine in human brain. J Nucl Med (1998) 0.85
Epibatidine analogues as selective ligands for the alpha(x)beta2-containing subtypes of nicotinic acetylcholine receptors. Bioorg Med Chem Lett (2005) 0.83
New synthesis and evaluation of enantiomers of 7-methyl-2-exo-(3'-iodo-5'-pyridinyl)-7-azabicyclo[2.2.1]heptane as stereoselective ligands for PET imaging of nicotinic acetylcholine receptors. Bioorg Med Chem Lett (2008) 0.83
Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl Radiat Isot (2004) 0.83
Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. J Neurochem (2004) 0.83
New-generation radiotracers for nAChR and NET. Nucl Med Biol (2005) 0.83
[18F]FPhEP and [18F]F2PhEP, two new epibatidine-based radioligands: evaluation for imaging nicotinic acetylcholine receptors in baboon brain. Synapse (2007) 0.83
Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Farmaco (2004) 0.82
Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent. J Pharmacol Exp Ther (1994) 0.81
Acetylenic pyridines for use in PET imaging of nicotinic receptors. ChemMedChem (2007) 0.81
A novel nicotinic acetylcholine receptor antagonist radioligand for PET studies. Bioorg Med Chem Lett (2005) 0.81
6-Chloro-3-(((1-[11C]methyl)-2-(S)-pyrrolidinyl)methoxy)-5-(2-fluoropyridin-4-yl)pyridine ([11C]JHU85270), a potent ligand for nicotinic acetylcholine receptor imaging by positron emission tomography. Appl Radiat Isot (2007) 0.80
NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. J Neurochem (2007) 0.80
Synthesis and evaluation of 6-[(18)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol (2000) 0.79
6-[18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl Med Biol (2000) 0.79
In vitro characterization of 6-[18F]fluoro-A-85380, a high-affinity ligand for alpha4beta2* nicotinic acetylcholine receptors. Synapse (2005) 0.79
Radiosynthesis of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-[(11)C]methyl-2-(S)-pyrrolidinylmethoxy)pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. Bioorg Med Chem (2001) 0.79
Nicotinic acetylcholine receptors and imaging. Curr Pharm Des (2000) 0.79
Synthesis and biological evaluation of pyridine-modified analogues of 3-(2-aminoethoxy)pyridine as novel nicotinic receptor ligands. Bioorg Med Chem Lett (2002) 0.78
Synthesis and radiosynthesis of [(18)F]FPhEP, a novel alpha(4)beta(2)-selective, epibatidine-based antagonist for PET imaging of nicotinic acetylcholine receptors. Bioorg Med Chem (2006) 0.78
Synthesis and evaluation of N-[11C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J Med Chem (1998) 0.78
Nicotine-11C: synthesis and distribution kinetics in animals. Eur J Nucl Med (1976) 0.77
In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(-)[11C]nicotine in rhesus monkeys. Nucl Med Biol (1999) 0.77
Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med (2013) 7.52
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology (2006) 2.15
Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology (2011) 2.13
Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res (2005) 2.10
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res (2008) 2.00
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry (2006) 1.87
Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse (2008) 1.66
Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology (2005) 1.51
11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging (2003) 1.49
Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J Am Coll Cardiol (2012) 1.49
Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry (2005) 1.48
Differences in brain structure and function in older adults with self-reported disabling and nondisabling chronic low back pain. Pain Med (2010) 1.46
Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med (2009) 1.44
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology (2002) 1.35
Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) (2008) 1.34
11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med (2006) 1.32
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology (2007) 1.30
Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology (2005) 1.30
The association between body mass index and health-related quality of life: data from CaMos, a stratified population study. Qual Life Res (2007) 1.26
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage (2010) 1.19
Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress. Neuropsychopharmacology (2007) 1.16
VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem (2007) 1.15
18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. J Nucl Med (2013) 1.15
Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology (2007) 1.14
Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer (2008) 1.14
Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry (2004) 1.12
Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med (2007) 1.11
Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med (2006) 1.09
Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. Neuroimage (2007) 1.09
Winter soil respiration from different vegetation patches in the Yellow River Delta, China. Environ Manage (2012) 1.05
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol (2007) 1.04
Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol (2003) 1.04
Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol (2008) 1.04
The role of the lateral dimension of graphene oxide in the regulation of cellular responses. Biomaterials (2012) 1.02
Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med (2002) 1.02
Laboratory-based surveillance of nontyphoidal Salmonella infections in China. Foodborne Pathog Dis (2011) 1.01
Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol (2012) 0.99
History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. Psychopharmacology (Berl) (2014) 0.99
Intravenous nicotine reduces cerebral glucose metabolism: a preliminary study. Neuropsychopharmacology (2002) 0.99
Drilling to gabbro in intact ocean crust. Science (2006) 0.98
Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) (2008) 0.97
[(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol (2002) 0.97
The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep (2011) 0.96
Direct 4D reconstruction of parametric images incorporating anato-functional joint entropy. Phys Med Biol (2010) 0.95
Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects. Alcohol Clin Exp Res (2011) 0.94
Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem (2010) 0.94
Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism. Biol Psychiatry (2004) 0.94
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett (2007) 0.93
Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors. J Labelled Comp Radiopharm (2013) 0.93
Naloxone-induced cortisol predicts mu opioid receptor binding potential in specific brain regions of healthy subjects. Psychoneuroendocrinology (2011) 0.92
Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behavior. J Nucl Med (2005) 0.92
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med (2009) 0.92
Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res (2006) 0.92
Radionuclide imaging of angiotensin II type 1 receptor upregulation after myocardial ischemia-reperfusion injury. J Nucl Med (2010) 0.91
PET OEF reactivity for hemodynamic compromise in occlusive vascular disease. J Neuroimaging (2007) 0.90
PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics. J Nucl Med (2011) 0.89
Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorg Med Chem (2005) 0.89
18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET. J Nucl Med (2014) 0.88
Identification of hemodynamic compromise by cerebrovascular reserve and oxygen extraction fraction in occlusive vascular disease. J Cereb Blood Flow Metab (2004) 0.88
Gender differences in nigrostriatal dopaminergic innervation are present at young-to-middle but not at older age in normal adults. J Clin Neurosci (2011) 0.87
Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep (2013) 0.87
individual variation in sleep quality and duration is related to cerebral mu opioid receptor binding potential during tonic laboratory pain in healthy subjects. Pain Med (2013) 0.86
Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors. J Med Chem (2013) 0.86
A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl Med Biol (2004) 0.86
Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology (2012) 0.86
Derivatives of (-)-7-methyl-2-(5-(pyridinyl)pyridin-3-yl)-7-azabicyclo[2.2.1]heptane are potential ligands for positron emission tomography imaging of extrathalamic nicotinic acetylcholine receptors. J Med Chem (2007) 0.86
Synthesis and biodistribution of [11C]adenosine 5'-monophosphate ([11C]AMP). Mol Imaging Biol (2005) 0.86
Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. Neuroimage (2011) 0.85
Supported Pd-Cu bimetallic nanoparticles that have high activity for the electrochemical oxidation of methanol. Chemistry (2012) 0.85
5-(5-(6-[(11)C]methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)-1H-indole as a potential PET radioligand for imaging cerebral α7-nAChR in mice. Bioorg Med Chem (2012) 0.85
Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands. J Nucl Med (2005) 0.85
Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. Mol Imaging Biol (2014) 0.84
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects. Addict Biol (2012) 0.84
In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J Nucl Med (2004) 0.84
New synthesis and evaluation of enantiomers of 7-methyl-2-exo-(3'-iodo-5'-pyridinyl)-7-azabicyclo[2.2.1]heptane as stereoselective ligands for PET imaging of nicotinic acetylcholine receptors. Bioorg Med Chem Lett (2008) 0.83
PET Imaging of the AT1 receptor with [11C]KR31173. Nucl Med Biol (2006) 0.83
Synthesis and evaluation of new radioligands [(11)C]A-833834 and [(11)C]A-752274 for positron-emission tomography of α7-nicotinic acetylcholine receptors. Nucl Med Biol (2013) 0.83